湖北济川药业股份有限公司关于2022年限制性股票与股票期权激励计划部分股票期权注销完成的公告

Core Points - The company announced the completion of the cancellation of certain stock options and the repurchase of restricted stocks as part of its 2022 incentive plan [2][3] - A total of 1,238,500 stock options will be canceled due to the departure, retirement, or demotion of certain incentive recipients [2] - The cancellation will not affect the company's capital structure or the ongoing implementation of the 2022 incentive plan [3] Summary by Sections - Incentive Plan Details - The company held meetings on July 22, 2024, and April 25, 2025, to approve the cancellation of stock options and repurchase of restricted stocks [2] - The canceled stock options include 869,000 from the initial grant, 279,500 from the first reserved grant, and 90,000 from the second reserved grant [2] - Regulatory Compliance - The company submitted the cancellation application to the China Securities Depository and Clearing Corporation Shanghai Branch, which confirmed the completion of the cancellation on August 6, 2025 [2] - Impact Assessment - The cancellation of stock options will not impact the company's capital structure or the continuation of the incentive plan [3]